These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 6489181

  • 1. [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
    Krüger N, Kijewski H, König R, Tillmann W, Schröter W.
    Dtsch Med Wochenschr; 1984 Nov 02; 109(44):1682-5. PubMed ID: 6489181
    [Abstract] [Full Text] [Related]

  • 2. Iron chelating therapy in thalassemia: current problems.
    Russo G.
    Haematologica; 1990 Nov 02; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract] [Full Text] [Related]

  • 3. [Continuous subcutaneous deferoxamine infusions in thalassemia major. Improvement in glucose tolerance].
    Krüger N, Stubbe P, Tillmann W, Schröter W.
    Dtsch Med Wochenschr; 1986 May 02; 111(18):698-701. PubMed ID: 3486106
    [Abstract] [Full Text] [Related]

  • 4. [Continuous subcutaneous deferoxamine treatment in thalassemia major. Decrease of hemosiderosis and improvement of liver function].
    Krüger N, Ullrich D, Tillmann W, Schröter W.
    Dtsch Med Wochenschr; 1985 Nov 29; 110(48):1848-51. PubMed ID: 4064938
    [Abstract] [Full Text] [Related]

  • 5. [Continuous subcutaneous desferrioxamine infusions in patients with hemosiderosis (author's transl)].
    Tillmann W, König R, Schröder K, Schröter W.
    Monatsschr Kinderheilkd; 1982 Mar 29; 130(3):171-2. PubMed ID: 7087975
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR, Mahony BS, Githens JH, Rhoades ED.
    Am J Pediatr Hematol Oncol; 1982 Mar 29; 4(2):115-23. PubMed ID: 7114394
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Iron metabolism and iron chelation in the thalassaemia disorders.
    Pippard MJ.
    Haematologica; 1990 Mar 29; 75 Suppl 5():66-71. PubMed ID: 2086383
    [No Abstract] [Full Text] [Related]

  • 11. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.
    Silliman CC, Peterson VM, Mellman DL, Dixon DJ, Hambidge KM, Lane PA.
    J Lab Clin Med; 1993 Jul 29; 122(1):48-54. PubMed ID: 8320490
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ferrioxamine excretion in iron-loaded man.
    Pippard MJ, Callender ST, Finch CA.
    Blood; 1982 Aug 29; 60(2):288-94. PubMed ID: 7093519
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combined long-term treatment of hemosiderosis with desferioxamine and DTPA in homozygous beta-thalassemia.
    Constantoulakis M, Economidou J, Karagiorga M, Katsantoni A, Gyftaki E.
    Ann N Y Acad Sci; 1974 Aug 29; 232(0):193-200. PubMed ID: 4528481
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.
    Hussain MA, Green N, Flynn DM, Hoffbrand AV.
    Lancet; 1977 May 07; 1(8019):977-9. PubMed ID: 67469
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Deferoxamine for the treatment of hemosiderosis during CAPD.
    Gomez RA, Campbell F, Savory J, Chevalier RL.
    Int J Pediatr Nephrol; 1987 May 07; 8(1):21-4. PubMed ID: 3583552
    [Abstract] [Full Text] [Related]

  • 20. [Current status of treatments with desferrioxamine B in post-transfusion hypersiderosis in children].
    Orsini A, Raybaud C, Bernard PJ, Aquaron R, Passeron P.
    Mars Med; 1967 May 07; 104(4):331-7. PubMed ID: 5621537
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.